CYTOSORBENTS CORPORATION (CTSO) Return on equity 2016–2025
CYTOSORBENTS CORPORATION (CTSO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-138.9%FY2025 · since FY2016: -879.5% → -138.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -138.9% | +47.7 pp |
| FY2024 | -186.5% | -62.0 pp |
| FY2023 | -124.6% | -31.8 pp |
| FY2022 | -92.8% | -53.5 pp |
| FY2021 | -39.2% | -29.4 pp |
| FY2020 | -9.9% | +553.8 pp |
| FY2019 | -563.6% | -462.0 pp |
| FY2018 | -101.6% | -19.2 pp |
| FY2017 | -82.4% | +797.1 pp |
| FY2016 | -879.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CTSO financial trends
CTSO RevenueCTSO Net incomeCTSO Net marginCTSO Gross profitCTSO Gross marginCTSO Operating incomeCTSO Operating marginCTSO Operating cash flowCTSO Free cash flowCTSO Capital expendituresCTSO Stock buybacksCTSO Dividends paidCTSO Total assetsCTSO Total liabilitiesCTSO Shareholders’ equityCTSO overview →